<DOC>
	<DOCNO>NCT00951873</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety , local tolerability pharmacokinetic profile ( determination concentration administer medication blood time ) long act activate recombinant human factor VII inject subcutaneously ( skin ) .</brief_summary>
	<brief_title>A Single Dose Trial Investigating Safety Local Tolerability Ascending Doses Long Acting Activated Recombinant Human Factor VII Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Caucasian origin Body weight 50 100 kg Body Mass Index ( BMI ) 18.0 28.0 kg/m2 inclusive Smoke le 10 cigarettes/day equivalent willingness abstain smoking entire duration Trial Product Administration ( 9 day ) Known suspect allergy trial product relate product , activate recombinant human factor VII ( NovoSevenÂ® ) Previous participation trial , define randomised receive trial product Evidence clinically relevant pathology potential thromboembolic risk judge Investigator Known history atherosclerosis thromboembolic event Overt bleeding , include gastrointestinal tract Hepatitis B C infection HIV infection Positive test drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>